Company intelligence / Profile preview
Inventiva
Daix, Bourgogne-Franche-Comté, Franceinventivapharma.com ↗
- Ownership
- Public · IVA
- Employees
- ~111
- Development stage
- Other
01
Overview
Inventiva’s lead candidate lanifibranor is in a pivotal Phase III trial (“NATiV3”) for NASH/MASH. Positive results were reported from the LEGEND Phase IIa study combining lanifibranor with empagliflozin in patients with NASH/MASH and type 2 diabetes in March 2024. The odiparcil program for MPS VI is suspended pending strategic review. Two additional preclinical programs are ongoing, including an oncology candidate targeting the Hippo pathway
- Therapeutic areas
- GastroenterologyOncologyRare Diseases
- Modalities
- Small molecules (oral)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
AbbVie – collaboration on ABBV‑157 for moderate to severe psoriasis; milestone payments and royalties possible if successful.Hepalys Pharma – exclusive licensing agreement to develop/commercialize lanifibranor in Japan/South Korea.Sino Biopharm – partnership/licensing agreement.CTTQ – milestone payments related to development of lanifibranor in China.
04
Financials
- Market cap
- $188.7M
- Total revenue
- $5M
- Enterprise value
- $77.6M
Beyond the preview
Go deeper on Inventiva.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inventiva.